Cargando…

Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)

The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Venema, K., Verhoeven, J., Verbruggen, S., Espinosa, L., Courau, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856813/
https://www.ncbi.nlm.nih.gov/pubmed/31454425
http://dx.doi.org/10.1111/lam.13211
_version_ 1783470649400885248
author Venema, K.
Verhoeven, J.
Verbruggen, S.
Espinosa, L.
Courau, S.
author_facet Venema, K.
Verhoeven, J.
Verbruggen, S.
Espinosa, L.
Courau, S.
author_sort Venema, K.
collection PubMed
description The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine. SIGNIFICANCE AND IMPACT OF THE STUDY: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.
format Online
Article
Text
id pubmed-6856813
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68568132019-11-21 Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1) Venema, K. Verhoeven, J. Verbruggen, S. Espinosa, L. Courau, S. Lett Appl Microbiol Original Articles The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine. SIGNIFICANCE AND IMPACT OF THE STUDY: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains. John Wiley and Sons Inc. 2019-10-09 2019-11 /pmc/articles/PMC6856813/ /pubmed/31454425 http://dx.doi.org/10.1111/lam.13211 Text en © 2019 The Authors. Letters in Applied Microbiology published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Venema, K.
Verhoeven, J.
Verbruggen, S.
Espinosa, L.
Courau, S.
Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
title Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
title_full Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
title_fullStr Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
title_full_unstemmed Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
title_short Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
title_sort probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (tim‐1)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856813/
https://www.ncbi.nlm.nih.gov/pubmed/31454425
http://dx.doi.org/10.1111/lam.13211
work_keys_str_mv AT venemak probioticsurvivalduringamultilayeredtabletdevelopmentastestedinadynamiccomputercontrolledinvitromodelofthestomachandsmallintestinetim1
AT verhoevenj probioticsurvivalduringamultilayeredtabletdevelopmentastestedinadynamiccomputercontrolledinvitromodelofthestomachandsmallintestinetim1
AT verbruggens probioticsurvivalduringamultilayeredtabletdevelopmentastestedinadynamiccomputercontrolledinvitromodelofthestomachandsmallintestinetim1
AT espinosal probioticsurvivalduringamultilayeredtabletdevelopmentastestedinadynamiccomputercontrolledinvitromodelofthestomachandsmallintestinetim1
AT couraus probioticsurvivalduringamultilayeredtabletdevelopmentastestedinadynamiccomputercontrolledinvitromodelofthestomachandsmallintestinetim1